| Identification | Back Directory | [Name]
NEUROPEPTIDE S (HUMAN) | [CAS]
412938-67-1 | [Synonyms]
NPS (HUMAN)
SFRNGVGTGMKKTSFQRAKS
NEUROPEPTIDE S (HUMAN)
Neuropeptide S, NPS, human
Neuropeptide S (huMan)
NPS (huMan)
SER-PHE-ARG-ASN-GLY-VAL-GLY-THR-GLY-MET-LYS-LYS-THR-SER-PHE-GLN-ARG-ALA-LYS-SER
H-SER-PHE-ARG-ASN-GLY-VAL-GLY-THR-GLY-MET-LYS-LYS-THR-SER-PHE-GLN-ARG-ALA-LYS-SER-OH
REF DUPL: H-Ser-Phe-Arg-Asn-Gly-Val-Gly-Ser-Gly-Ala-Lys-Lys-Thr-Ser-Phe-Arg-Arg-Ala-Lys-Gln-OH | [Molecular Formula]
C93H155N31O28S | [MDL Number]
MFCD07368606 | [MOL File]
412938-67-1.mol | [Molecular Weight]
2187.48 |
| Hazard Information | Back Directory | [Biological Activity]
Neuropeptide S human is a potent endogenous neuropeptide S receptor agonist (EC50=9.4 nM). It (TFA) increases motor activity and wakefulness in mice, and has potential for Alzheimer's disease (AD) research. | [in vitro]
Neuropeptide S human (4 pM to 1.7 nM; 48 hours) retains full agonist activity with an EC 50 of 6.7 ± 2.4 nM, the binding of [ 125I ] Y10-hNPS to CHO cells stably expressing hNPSR is saturable with high affinity (K d = 0.33 ± 0.12 nM). Neuropeptide S human (1 pM-3 μM; 48 hours) are used to compete with 0.15 nM [ 125I I] Y10-NPS, [ 125I I] Y10-NPS is displaceable by increasing concentrations of human NPS (IC 50 = 0.42 ± 0.12 nM). | [in vivo]
Neuropeptide S human (0.1 nM-1 nM; icv) causes a significant increase in locomotor activity, the total distance traveled, percentage of time moving, number of rearing events, and center entries are also significantly increased in mice . | Animal Model: | Male C57Bl/6 mice | | Dosage: | 0.1 nM, 1 nM | | Administration: | Intracerebroventricular (icv) injection | | Result: | Increased locomotor activity and promoted wakefulness. | | [target]
EC50: 9.4 nM (neuropeptide S receptor) |
|
|